Angiogenesis and Minimal Residual Disease in Patients with Acute Myeloid Leukemia

Overview

Journal Int J Hematol Oncol Stem Cell Res

Specialty Hematology

Date 2020 May 29

PMID 32461792

Citations 1

Authors

Pardis Nematollahi

Azar Baradaran

Zahra Kasaei Koopaei

Hamidreza Sajjadieh

Affiliations

Soon will be listed here.

Abstract

Acute myeloid leukemia (AML) is the most prevalent acute leukemia in adults. Bone marrow angiogenesis is crucial for pathogenesis of leukemia, and increasing bone marrow Mean Vascular Density (MVD) and level of angiogenesis factors are seen in patients with AML. Higher level of bone marrow MVD is associated with poor prognosis of AML according to previous studies. The present study aimed to compare bone marrow MVD in AML patients and controls and evaluate the relation between bone marrow MVD and number of residual blast cells after AML treatment. This study is a longitudinal study on AML patients who were admitted to Omid hospital. The bone marrow biopsies of patients with AML and patients with normal diagnosis -as control group- were taken from archives of pathology laboratory. Immunohistochemistry staining was used for all specimens by using thrombomodulin markers for calculating MVD. Flow cytometry findings of AML patients were assessed for percent of minimal residual disease (MRD) after AML treatment in AML patients group. In this study, 27 AML patients and 24 healthy individuals with mean age of 40.92±15.13 years were evaluated, of whom 56.86% were male. The mean bone marrow MVD was significantly higher in AML patients than controls. The mean bone marrow MVD was significantly higher in males and there was insignificant reverse correlation between bone marrow MVD and MRD. About 59.3% of AML patients had response to treatment and there was no significant relationship between MVD and response to treatment. Bone marrow MVD was higher in AML patients than controls and there was no remarkable relationship between bone marrow MVD and MRD and response to treatment.

Citing Articles

Identification and validation of a novel CD8+ T cell-associated prognostic model based on ferroptosis in acute myeloid leukemia.

Jiang G, Jin P, Xiao X, Shen J, Li R, Zhang Y Front Immunol. 2023; 14:1149513.

PMID: 37138885 PMC: 10150955. DOI: 10.3389/fimmu.2023.1149513.

References

Kuzu I, Beksac M, Arat M, Celebi H, Elhan A, Erekul S . Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival. Leuk Lymphoma. 2004; 45(6):1185-90. DOI: 10.1080/1042819032000159915. View

Soignet S, Fleischauer A, Polyak T, Heller G, Warrell Jr R . All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study. Cancer Chemother Pharmacol. 1997; 40 Suppl:S25-9. DOI: 10.1007/s002800051057. View

Fenaux P, Le Deley M, Castaigne S, Archimbaud E, Chomienne C, Link H . Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood. 1993; 82(11):3241-9. View

Hussong J, Rodgers G, Shami P . Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 1999; 95(1):309-13. View

Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J . Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2001; 95(8):2637-44. View

Todorovic M, Radisavljevic Z, Balint B, Andjelic B, Todorovic V, Perunicic Jovanovic M . Increased angiogenesis-associated poor outcome in acute lymphoblastic leukemia: a single center study. Appl Immunohistochem Mol Morphol. 2012; 20(5):488-93. DOI: 10.1097/PAI.0b013e3182414c3b. View

Moorman A, Chilton L, Wilkinson J, Ensor H, Bown N, Proctor S . A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2009; 115(2):206-14. DOI: 10.1182/blood-2009-07-232124. View

Buccisano F, Maurillo L, Del Principe M, Del Poeta G, Sconocchia G, Lo-Coco F . Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood. 2011; 119(2):332-41. DOI: 10.1182/blood-2011-08-363291. View

Negaard H, Iversen N, Bowitz-Lothe I, Sandset P, Steinsvik B, Ostenstad B . Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia. 2008; 23(1):162-9. DOI: 10.1038/leu.2008.255. View

10.

Hung C, Yang S, Kuo P, Chu Y, Chang H, Wei W . Modulation of cytokine expression in human myeloid dendritic cells by environmental endocrine-disrupting chemicals involves epigenetic regulation. Environ Health Perspect. 2010; 118(1):67-72. PMC: 2831970. DOI: 10.1289/ehp.0901011. View

11.

Song Y, Tan Y, Liu L, Wang Q, Zhu J, Liu M . Levels of bone marrow microvessel density are crucial for evaluating the status of acute myeloid leukemia. Oncol Lett. 2015; 10(1):211-215. PMC: 4487085. DOI: 10.3892/ol.2015.3209. View

12.

Kvasnicka H, Thiele J . Bone marrow angiogenesis: methods of quantification and changes evolving in chronic myeloproliferative disorders. Histol Histopathol. 2004; 19(4):1245-60. DOI: 10.14670/HH-19.1245. View

13.

Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D . Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000; 96(6):2240-5. View

14.

Ghavamzadeh A, Alimoghaddam K, Ghaffari S, Rostami S, Jahani M, Hosseini R . Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2005; 17(1):131-4. DOI: 10.1093/annonc/mdj019. View

15.

Dohner H, Weisdorf D, Bloomfield C . Acute Myeloid Leukemia. N Engl J Med. 2015; 373(12):1136-52. DOI: 10.1056/NEJMra1406184. View

16.

Li W, Hutnik M, Gehr G . Antiangiogenesis in haematological malignancies. Br J Haematol. 2008; 143(5):622-31. DOI: 10.1111/j.1365-2141.2008.07372.x. View

17.

Mangi M, Newland A . Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol. 2000; 111(1):43-51. DOI: 10.1046/j.1365-2141.2000.02104.x. View

18.

San Miguel J, Martinez A, Macedo A, Vidriales M, Gonzalez M, Caballero D . Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood. 1997; 90(6):2465-70. View